Predictive importance of left ventricular myocardial stiffness for the prognosis of patients with congestive heart failure  by Watanabe, Satoshi et al.
Journal of Cardiology (2011) 58,  245—252
av ai lab le at www.sc iencedi rec t .com
jou rna l h om epage: www.elsev ier .com/ locate / j j cc
Original article
Predictive  importance  of  left  ventricular  myocardial
stiffness  for  the  prognosis  of  patients  with
congestive  heart  failure
Satoshi  Watanabe  (MD)a,∗,  Junya  Shite  (MD,  FJCC)a,  Hideyuki  Takaoka  (MD)a,
Toshiro  Shinke  (MD,  FJCC)a,  Yusuke  Tanino  (MD)a,  Hiromasa  Otake  (MD)a,
Daisuke  Matsumoto  (MD)a,  Daisuke  Ogasawara  (MD)a,
Takahiro  Sawada  (MD)a,  Ken-ichi  Hirata  (MD)a,
Mitsuhiro  Yokoyama  (MD,  FJCC)b
a Division  of  Cardiovascular  and  Respiratory  Medicine,  Department  of  Internal  Medicine,  Kobe  University  Graduate  School  of
Medicine, Kobe,  Japan
b Department  of  Cardiology,  Hyogo  Brain  and  Heart  Center  at  Himeji,  Himeji,  Japan
Received 17  September  2010;  received  in  revised  form  17  June  2011;  accepted  7  July  2011








Objectives:  This  study  was  designed  to  determine  the  prognostic  importance  of  left  ventricular
(LV) myocardial  stiffness,  a  hemodynamic  index  which  is  closely  related  to  B-type  natriuretic
peptide  (BNP)  concentration  in  patients  with  congestive  heart  failure  (CHF).
Background:  While  elevated  BNP,  an  abnormality  of  cardiac  neurohormones,  is  known  to  be  an
independent  marker  of  death  or  re-admission,  it  remains  to  be  clariﬁed  whether  there  is  also
a strong  predictor  directly  related  to  cardiac  dysfunction.
Methods:  LV  performance  variables  and  stress—strain  analyses  including  diastolic  myocardial
stiffness constant  (Km)  were  obtained  from  37  patients  with  initial  CHF  by  the  combined  simul-
taneous measurement  of  echocardiographic  and  hemodynamic  data.  Survivors  were  monitored
for a  mean  of  23  months,  with  the  main  endpoint  being  combined  death  or  ﬁrst  re-admission
for CHF.
Results:  Ten  patients  (27%)  were  primary  endpoint  cases.  Both  Km and  plasma  BNP  levels  were
higher in  the  event  than  in  the  event-free  group.  By  Cox  proportional  hazards  analysis,  Km ≥  4.0
was identiﬁed  as  the  only  variable  with  signiﬁcant  and  independently  incremental  predictive
power to  affect  the  primary  endpoint  (adjusted  hazard  ratio  =  7.354,  95%  conﬁdence  interval
1.379—39.232,  p  =  0.02).
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Conclusions:  In  patients  with  CHF,  increased  myocardial  stiffness  may  have  greater  prognostic
signiﬁcance  compared  to  other  conventional  predictors.  Increased  myocardial  stiffness  may  be




























































































images  according  to  standard  criteria  [23]. Pulsed  Doppler
analysis  of  mitral  inﬂow  included  measurements  of  LV  inﬂow
early  peak  ﬁlling  velocity  (E),  late  peak  ﬁlling  velocityconsidered to  be  an  importan
© 2011  Japanese  College  of  C
ntroduction
eart  failure  has  become  one  of  the  major  causes  of  death
s  the  elderly  population  has  been  increasing.  Hospital-
zation  for  congestive  heart  failure  (CHF)  carries  a  poor
rognosis  with  frequent  subsequent  re-admissions  [1—5].
espite  the  substantial  evidence  of  the  lifesaving  beneﬁts
f  beta-blockers  for  patients  with  CHF  [6—8], there  are
till  many  patients  who  suffer  from  recurrent  decompen-
ation.  Conventional  predictors  for  CHF  prognosis  include
emodynamic  variables  such  as  left  ventricular  (LV)  ejec-
ion  fraction  (LVEF),  LV  end-diastolic  pressure  (LVEDP)  (both
re  well-known  predictors  of  mortality),  end-diastolic  vol-
me  index,  or  pulsed  Doppler  analysis  of  mitral  inﬂow
9].  However,  the  predictive  accuracy  of  these  cardiac
ariables  is  not  satisfactory  [10,11].  Reported  ﬁndings  indi-
ate  that  B-type  natriuretic  peptide  (BNP),  a  well-known
ardiac  neurohormone  speciﬁcally  secreted  from  the  car-
iac  ventricles  in  response  to  ventricular  overload  [12—14],
s  an  independent  marker  of  cardiac  survival  [10,15—17],
lthough  pre-  and  post-discharge  BNP  values  vary  widely
n  the  same  patient  because  of  changes  in  cardiac  load-
ng  conditions.  Recently,  we  have  shown  that  the  baseline
NP  concentration  is  strongly  related  to  LV  myocardial
tiffness  [18], which  is  considered  to  be  an  essential
yocardial  diastolic  property  independent  of  loading  con-
itions  [19]. Despite  its  potential  importance,  it  is  still
nknown  whether  or  how  these  novel  indexes  can  pre-
ict  post-discharge  outcomes  for  patients  admitted  for
HF.
The  aim  of  our  study  is  to  determine  whether  the  novel
ndex  of  passive  diastolic  myocardial  stiffness  can  help  pre-
ict  major  cardiac  events  such  as  death  or  re-admission  for
onsecutive  patients  hospitalized  for  acute  CHF.
ethods
tudy  design
onsecutive  patients  admitted  between  July  2003  and
ovember  2005  for  initial  decompensated  CHF  were  eligible,
ith  the  following  exceptions:  acute  myocardial  infarc-
ion,  prior  Q-wave  myocardial  infarction,  renal  dysfunction
deﬁned  as  a  creatinine  value  ≥2.0  mg/dl),  signiﬁcant
alve  diseases,  atrial  ﬁbrillation,  signiﬁcant  coronary  artery
tenosis  (>50%),  or  poor  adherence  to  therapy.  The  diag-
osis  of  CHF  was  based  on  the  Framingham  criteria  [20].
teady-state  plasma  BNP  levels  were  obtained  following
reatment  with  appropriate  medications  [21], clinical  sta-
ilization,  and  thorough  diuresis.  The  patients  were  then
xamined  by  means  of  combined  simultaneous  measure-
ents  of  echocardiographic  and  hemodynamic  data,  after
hich  LV  performance  variables  and  stress—strain  analyses
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atients
nitially,  57  CHF  patients  who  met  the  criteria  were  enrolled,
ut  12  were  excluded  from  the  study  because  they  had
ot  given  informed  consent,  and  a  further  eight  patients
ecause  of  the  poor  quality  of  echocardiographic  images.
inally,  37  (65%)  patients  (63  ±  12  years,  range  33—80  years)
ere  enrolled  in  the  study.  The  etiologies  of  heart  failure  for
he  study  population  were  hypertensive  heart  disease  for  19
51%)  and  non-ischemic  idiopathic  dilated  cardiomyopathy
or  18  (49%)  patients.
NP  assays
NP  assays  were  obtained  before  examination  according
o  previously  described  methods  [22]. In  brief,  the  blood
amples  were  withdrawn  into  plastic  syringes,  transferred
o  chilled  siliconized  disposable  tubes  containing  aprotinin
1000  kallikrein  inactivator  units/ml)  and  EDTA  (1  mg/ml),
mmediately  placed  on  ice,  and  then  centrifuged  at  4 ◦C.  An
liquot  of  the  plasma  was  immediately  frozen  at  −80 ◦C,  and
he  plasma  BNP  concentration  was  measured  with  a  speciﬁc
mmunoradiometric  assay  kit  (Shionogi  Co.,  Osaka,  Japan).
tudy  protocol
fter  right  heart  catheterization  to  measure  the  pulmonary
apillary  wedge  pressure  (PCWP),  left  ventriculography  was
erformed  to  measure  the  LVEF  and  LV  end-diastolic  and
nd-systolic  volume  indices  (LVEDVI,  LVESVI,  respectively),
hich  were  derived  from  a single-plane  angiogram  by  means
f  the  area-length  method.  Next,  LV  dimensions  and  wall
hickness  were  assessed  by  echocardiography,  while  the  LV
ressure  was  measured  simultaneously.  To  alter  the  sys-
olic  blood  pressure  for  more  than  15  mmHg,  phenylephrine
ydrochloride  (0.1—0.5  mg)  was  administered  intravenously.
ll  data  were  recorded  on  high-speed  paper  for  off-line
nalysis.
chocardiographic  measurement
-mode  recordings  were  obtained  with  commercially  avail-
ble  equipment  (SONOS  5500TM;  Agilent  Technologies  Inc.,
alo  Alto,  CA,  USA)  operating  at  2.5  MHz.  Two-dimensional
maging  examinations  were  performed  in  the  standard
anner  of  parasternal  long-  and  short-axis  views  and  LV
imensions  and  wall  thickness  was  measured  on  M-modeA),  E-to-A ratio,  and  deceleration  time  of  the  E-wave
DTE).  Findings  were  categorized  into  three  patterns:  1)
n  ‘‘impaired  relaxation’’  pattern  (E/A  ratio  <  1);  2)  a















































cPrognostic  value  of  myocardial  stiffness  in  CHF  
DTE  ≤  130  ms);  and  3)  a  ‘‘pseudonormal’’  or  ‘‘normalized’’
pattern  (E/A  ratio  between  1  and  2  and  DTE  >  130  ms).  LV
mass  was  calculated  with  a  formula  derived  from  the  method
of  Devereux  et  al.  [24]. Measurements  were  performed  by
two  experienced  observers  unaware  of  the  clinical  data.
LV  pressure  measurement
A  6F  high-ﬁdelity  micromanometer  catheter  (CENTRONTM;
Centron  International  Inc.,  Mineral  Wells,  TX,  USA)  was
inserted  into  the  middle  of  the  LV  cavity  to  measure  the  LV
end-systolic  pressure  (LVESP),  LVEDP,  and  the  time  constant
of  the  LV  isovolumic-pressure  decline  ().    was  calculated
with  the  method  of  Weiss  et  al.  [25].
Data  analyses
Chamber  stiffness  can  be  quantiﬁed  by  examining  the  rela-
tionship  between  diastolic  pressure  and  volume.  The  oper-
ating  stiffness  at  any  point  along  a  given  pressure—volume
curve  is  equal  to  the  slope  of  a  tangent  drawn  to  the  curve
at  that  point  (dP/dV).  Since  the  diastolic  pressure—volume
relationship  is  curvilinear  and  generally  exponential,  the
relationship  between  dP/dV  and  pressure  is  linear.  This  slope
is  called  the  modulus  of  chamber  stiffness  (diastolic  cham-
ber  stiffness  constant,  Kc)  and  can  be  used  as  a  single
numerical  value  to  quantify  chamber  stiffness.
Stress—strain  relationships  were  calculated  by  using
a  cylindrical  model  of  LV  geometry.  We  used  a  simpli-
ﬁed  echocardiographic  and  hemodynamic  method  to  assess
stress—strain  relationships  in  humans,  which  were  then
determined  with  the  modiﬁed  method  of  Esposito  et  al.
[26,27].  Meridional  stress  ()  of  the  LV  mid-wall  was  cal-
culated  as    =  P  ×Dm/[h  × (1 +  h/Dm)],  where  P  is  the  LV
pressure,  Dm is  the  instantaneous  mid-wall  short-axis  diam-
eter  of  the  LV,  and  h  is  the  LV  wall  thickness  [28]. Natural
strain  (ε)  was  deﬁned  as  ε  =  ln(Dm/Dom),  where  Dom is  the
zero-stress  mid-wall  short-axis  diameter.
Myocardial  stiffness  can  be  quantiﬁed  by  determining
the  relationship  between  myocardial  stress  ()  and  strain
(ε)  during  diastole.  At  any  given  strain,  myocardial  stiff-
ness  is  equal  to  the  slope  (d/dε)  of  a  tangent  drawn
to  the  stress—strain  relationship  at  that  strain.  Since  the
stress—strain  relationship  is  curvilinear  and  exponential,  the
relationship  between  (d/dε)  and  stress  is  linear,  and  the
slope  of  this  relationship  is  the  modulus  of  myocardial  stiff-
ness  (diastolic  myocardial  stiffness  constant,  Km).  Thus,  Km
is  a  dimensionless  constant  that  represents  the  myocardial
passive  diastolic  properties  [19].
Follow-up  and  endpoints
When  patients  had  recovered  from  CHF  and  become  stable,
they  were  discharged  and  monitored  at  the  outpatient  clinic
every  month.  The  primary  endpoint  was  the  combined  risk
of  cardiac  mortality  or  re-hospitalization  for  CHF.  Only  one







ategorical  data  are  presented  as  numbers  (%),  and  continu-
us  data  as  mean  ±  SD.  Natural  log  transformation  was  used
or  BNP  values  because  of  skewed  distribution.  Fisher’s  exact
est  was  used  for  dichotomous  variables,  and  the  unpaired  t
est  for  continuous  variables.  The  receiver-operating  char-
cteristic  (ROC)  curve  was  calculated  to  assess  the  utility  of
m to  distinguish  between  survivors  and  patients  who  were
ombined  endpoint  cases.  Survival  free  for  the  primary  end-
oint  for  CHF  was  estimated  with  the  Kaplan—Meier  method,
nd  the  differences  were  assessed  with  the  log-rank  test.
ox  proportional  hazards  regression  analysis  to  determine
he  incremental  prognostic  power  of  outcome  predictors  was
erformed  with  the  forced  entry  method.  A  p-value  of  less
han  0.05  was  considered  to  indicate  statistical  signiﬁcance.
ll  reported  p-values  are  two-sided.
esults
aseline  patient  characteristics
f  the  37  patients  admitted  to  our  institution  with  a  clinical
iagnosis  of  CHF,  follow-up  was  completed  for  all  patients
mean  time  interval  from  hospital  discharge  to  follow-up  was
3  ±  7  months).  The  pre-discharge  heart  failure  status  of  25
atients  was  New  York  Heart  Association  (NYHA)  class  II,  that
f  the  remaining  12  was  class  III.  Ten  patients  (27%)  were
rimary  endpoint  cases  (event  group:  2  cardiac  deaths,  8  re-
dmissions  for  CHF).  There  were  no  differences  between  the
vent  and  the  no-event  group  in  age,  gender,  and  medical
reatments,  and  the  only  difference  in  the  baseline  clini-
al  characteristics  was  the  pre-discharge  incidence  of  NYHA
lassiﬁcation  III  [event  group:  60%  (6  patients);  no-event
roup:  22%  (6  patients);  p  =  0.049]  (Table  1).
aseline  echocardiographic  and  hemodynamic
ariables  and  plasma  BNP  level
rom  the  echocardiographic  indices  we  found  that  end-
iastolic  posterior  wall  thickness,  mitral  E/A,  and  frequency
f  Doppler  mitral  ‘‘restrictive’’  pattern  in  the  event  group
ere  higher  than  those  in  the  no-event  group  (p  =  0.031,
.014,  0.009,  respectively)  (Table  2).  The  stress—strain  anal-
sis  results  showed  that  Kc and  Km were  higher  in  the
vent  group  than  in  the  no-event  group  (p  =  0.010,  0.001,
espectively)  (Table  3),  while  plasma  BNP  in  the  event
roup  was  at  a  signiﬁcantly  higher  level  (363.0  ±  284.2  vs.
44.9  ±  116.2  pg/ml,  respectively,  p  =  0.002)  (Table  3).  No
igniﬁcant  correlation  was  observed  between  Km and  LVEDP
R2 =  0.014)  (Fig.  1).
rognosis  of  patients  with  CHF
he  ROC  curve  analysis  identiﬁed  Km ≥  4.0  [area  under
urve  (AUC)  =  0.80,  CI  =  0.65—0.96],  p  =  0.005,  sensitivity
0%,  speciﬁcity  89%]  as  the  optimal  cut-off  point  for  pre-
iction  of  the  primary  endpoint  (Fig.  2).  The  Kaplan—Meier
urves  for  Km ≥  4.0  are  shown  in  Fig.  3.  Finally,  by  Cox  pro-
ortional  hazards  analysis  of  the  clinical  variables,  including
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Table  1  Baseline  patient  characteristics.
Variable,  n  (%)  Event  n  =  10  No-eventn  =  27  p-value
Age  (years)  67  ±  9  61  ±  12  0.158
Gender (male)  9  (90)  18  (67)  0.229
Diabetes 5  (50)  7  (26)  0.240
Hypertension  6  (60)  21  (78)  0.407
NYHA classiﬁcation  on  pre-discharge,  II/III  4  (40)/6  (60)  21  (78)/6  (22)  0.049/0.049
ACEI/ARB 10  (100)  27  (100)  NS
Nitrates 4  (40) 6  (22)  0.407
Diuretics 10  (100) 27  (100) NS
Beta-blockers,  pre-discharge/post-discharge 0  (0)/10  (100) 0  (0)/27  (100) NS/NS
Calcium channel  blockers 2  (20) 6  (22) NS
ACEI/ARB, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers; NS = not signiﬁcant; NYHA = New York Heart Asso-
ciation.
Data are presented as mean ± SD or number of patients (%).
Table  2  Baseline  echocardiographic  variables  according  to  patient  outcome.
Variable  Event  n  =  10  No-eventn  =  27  p-value
LV  end-diastolic  diameter  (mm)  52.0  ±  12.5  53.9  ±  10.3  0.647
LV end-systolic  diameter  (mm)  38.7  ±  13.9  41.3  ±  12.9  0.595
LV end-diastolic  posterior  wall  thickness  (mm)  11.7  ±  3.4  9.5  ±  2.3  0.031
LV end-systolic  posterior  wall  thickness  (mm)  15.2  ±  4.0  13.0  ±  3.9  0.135
LV fractional  shortening  (%)  30.9  ±  13.1  28.5  ±  14.1  0.639
Mitral E/A  1.56  ±  0.96  0.94  ±  0.50  0.014
Mitral deceleration  time  (cm/s)  174.1  ±  65.3  217.9  ±  61.1  0.659
Doppler mitral  patterna
‘‘Impaired  relaxation’’  pattern  4  (40)  19  (70)  0.132
‘‘Restrictive’’  pattern  5  (50)  2  (8)  0.009
‘‘Pseudonormal’’  or  ‘‘normalized’’  pattern  1  (10)  6  (22)  0.647
LV mass  index  (g/m2)  134  ±  27  124  ±  37  0.451
E/A, mitral valve early/late peak ﬁlling velocity; LV, left ventricular.
Data are presented as mean ± SD or number of patients (%).
a For an explanation of the patterns, see Methods (echocardiographic measurement).
Table  3  Baseline  hemodynamic  variables  and  plasma  B-type  natriuretic  peptide  according  to  patient  outcome.
Variable  Event  n  =  10  No-eventn  =  27  p-value
LV  end-diastolic  volume  index  (ml/m2)  110  ±  38  98  ±  27  0.284
LV end-systolic  volume  index  (ml/m2)  63  ±  41  54  ±  32  0.501
LV ejection  fraction  (%)  45  ±  15  46  ±  17  0.841
Pulmonary capillary  wedge  pressure  (mmHg)  17  ±  7  13  ±  5  0.094
LV end-diastolic  pressure  (mmHg) 16  ±  6  14  ±  6  0.431
LV end-systolic  pressure  (mmHg) 138 ±  39  140  ±  33  0.862
Time constant  of  the  LV  isovolumic-pressure  decline  ()  (ms) 55 ±  10  49 ±  20  0.376
LV end-diastolic  stress  (g/cm2)  60.6  ±  28.1  56.2  ±  36.2  0.732
LV end-systolic  stress  (g/cm2)  257.7  ±  130.6  290.1  ±  144.9  0.539
Diastolic chamber  stiffness  constant  (Kc)  0.077  ±  0.056  0.038  ±  0.030  0.010
Diastolic myocardial  stiffness  constant  (Km)  4.340  ±  1.284  3.040  ±  0.842  0.001
B-type natriuretic  peptide  (pg/ml)  363.0  ±  284.2  144.9  ±  116.2  0.002
LV, left ventricular.
Data are presented as mean ± SD.
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Table  4  Hazard  ratios  of  predictors  for  clinical  outcome  with  and  without  adjustment.
Predictors,  numbers  (%)  Event
n  =  10
No-event
n  =  27
Unadjusted
HR  (95%  CI)
p-value
Adjusted  HR  (95%  CI)
Elderly  (age  ≥65  years  old) 7(70.0)  11(40.7)  2.124  (0.539—8.362)  0.281
1.398  (0.212—9.219)  0.728
Diabetes (yes)
5(50.0)  7(25.9)  1.752  (0.504—6.087)  0.378
1.878  (0.510—6.911)  0.343
Elevated PCWP  (≥18  mmHg) 5(50.0)  3(11.1)  4.877  (1.397—17.026)  0.013
2.173  (0.317—14.882)  0.429
Elevated Km (≥4) 6(60.0)  3(11.1)  9.422  (2.329—38.276)  0.002
7.354  (1.379—39.232)  0.020
HR, hazard ratio; PCWP, pulmonary capillary wedge pressure; Km, diastolic myocardial stiffness constant.
Figure  1  No  signiﬁcant  correlation  was  observed  between
Figure  2  The  receiver-operating  characteristics  (ROC)  curve
illustrates  the  sensitivity  and  speciﬁcity  of  diastolic  myocardial










no  differences  between  patients  who  reached  the  primarymyocardial  stiffness  constant  (Km)  and  left  ventricular  end-
diastolic pressure  (LVEDP)  (R2 =  0.014).
those  that  an  epidemiological  approach  has  shown  to  affect
outcome,  Km ≥  4.0  was  identiﬁed  as  the  only  signiﬁcant  and
independent  predictor  for  the  primary  endpoint  (adjusted
hazard  ratio  =  7.354,  95%  conﬁdence  interval  1.379—39.232,
p  =  0.02)  (Table  4).  Plasma  BNP  level  was  not  included  from
the  multivariate  analysis  because  of  the  multicollinearity
between  Km [18].
Discussion
Although  many  previous  studies  have  demonstrated  that  ele-
vated  BNP  is  a  useful  neurohormonal  prognostic  marker  for
CHF,  it  is  still  not  known  whether  this  cardiac  dysfunction
is  strongly  associated  with  long-term  prognosis.  We  have
reported  previously  that  in  patients  with  CHF,  plasma  BNP
concentration  more  closely  correlates  with  passive  myocar-
dial  stiffness,  which  is  an  independent  factor  of  cardiac
loading  conditions  than  any  other  hemodynamic  variables
including  end-diastolic  stress  [18]. To  the  best  of  our  knowl-
edge,  this  is  the  ﬁrst  study  to  assess  the  prognostic  value
e
s
aeached  the  primary  end-point  from  survivors.  Km =  4.0  [area
nder curve  =  0.80,  p  =  0.005].
f  passive  myocardial  stiffness  for  determining  patient  out-
ome  in  CHF.
rognostic  importance  of  myocardial  stiffness
ompared to  conventional  hemodynamic  predictors
ur  study  found  that  conventional  echocardiographic  and
emodynamic  parameters  did  not  add  a  signiﬁcant  contri-
ution  to  the  predictive  power  of  Km and  BNP.  There  werendpoint  and  patients  who  did  not  in  terms  of  LV  fractional
hortening,  LV  mass  index,  LVEDVI,  LVEF,  PCWP,  LVEDP,  ,
nd  end-diastolic  stress.  On  the  other  hand,  pre-discharge
250  
Figure  3  Kaplan—Meier  analysis  results  showing  cumulative
rates of  event-free  survival  for  37  patients  with  congestive  heart
failure stratiﬁed  into  two  groups  according  to  results  of  the
receiver-operating  characteristics  curve  analysis.  Patients  with

























































































dantly  better  event-free  survival  than  did  patients  with  Km ≥  4.0
p =  0.0001).
lasma  BNP  levels  were  signiﬁcantly  higher  in  the  event
han  in  the  no-event  group.  Furthermore,  the  Doppler  mitral
‘restrictive’’  pattern,  Kc and  Km were  signiﬁcantly  higher
n  the  former.  The  Doppler  mitral  ‘‘restrictive’’  pattern  is
idely  used  as  a  prognostic  index  for  adverse  outcome  [29],
hile  LV  chamber  stiffness  (Kc)  is  known  to  reﬂect  the  degree
f  LV  remodeling  and/or  enlargement  [30]. Furthermore,
lterations  in  chamber  stiffness  may  reﬂect  changes  in  pas-
ive  myocardial  stiffness  as  well  as  in  other  factors  such
s  loading  conditions,  wall  thickness,  and  LV  geometry.  The
esults  of  our  study  indicate  that  the  parameters  of  LV  size,
uch  as  LV  mass  index  or  LVEDVI,  were  not  signiﬁcant  but
ended  to  be  larger  in  the  event  than  in  the  no-event  group.
c is  therefore  considered  to  be  a  more  sensitive  index  of
V  remodeling  and  enlargement,  although  in  this  study  the
oppler  mitral  ‘‘restrictive’’  pattern  and  chamber  stiffness
id  not  add  to  its  predictive  power,  since  these  variables
re  inﬂuenced  by  the  underlying  hemodynamic  abnormal-
ties  including  myocardial  systolic  or  diastolic  properties.
yocardial  stiffness,  on  the  other  hand,  is  considered  to  be
n  essential  myocardial  diastolic  property  independent  of
he  loading  conditions  [19].
echanism  of  increased  myocardial  stiffness  as  a
rognostic  marker  for  CHF  patients
ox  proportional  hazards  analysis  performed  in  our  study
isclosed  that  Km was  the  only  signiﬁcant  and  independent
redictor  of  the  primary  endpoint.  We  consider  that  one
ossible  reason  for  this  is  that,  when  we  performed  our
xamination,  our  study  subjects  had  become  clinically  sta-
ilized  in  terms  of  their  general  and  physical  condition  and
ad  been  thoroughly  diuresed  by  the  optimal  treatment.  As result,  the  volume  and/or  pressure  overload  to  the  LV  had
een  attenuated  to  the  minimum  level  in  every  patient,  so
hat  the  value  of  BNP  under  these  conditions  is  probably
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NP  has  proven  to  be  an  excellent  marker  of  cardiac  dis-
ase  compared  to  LV  ﬁlling  pressure.  On  the  other  hand,
yocardial  stiffness  is  considered  to  be  an  essential  dias-
olic  property,  since  it  is  comparatively  less  inﬂuenced  by
ardiac  morphologic  variables  and  supposed  to  reﬂect  the
egree  of  progressive  interstitial  LV  ﬁbrosis  regardless  of  the
ype  of  heart  failure.
We  consider  that  increased  myocardial  stiffness  in  CHF
atients  represents  a  transition  from  compensated  to
ecompensated  heart  failure  in  conjunction  with  progres-
ive  interstitial  LV  ﬁbrosis  [31,32]. In  the  failing  heart,
hanges  in  the  myocardial  ﬁbrillar  collagen  matrix  inﬂuence
yocardial  stiffness  characteristics.  Although  analysis  of  the
recise  mechanism  of  the  increase  in  myocardial  stiffness  in
ur  patients  is  beyond  the  goal  of  this  study,  this  increase
as  been  attributed  to  various  factors.  Experimental  studies
f  augmented  myocardial  diastolic  stiffness  in  spontaneous
ypertensive  rat  hearts  showed  that  myocardial  hydrox-
proline  concentrations  increased  and  myocardial  collagen
henotype  ratios  (type  I/type  III)  were  altered  [33]. Simi-
arly,  such  an  augmentation  in  diabetic  cardiomyopathy  was
ound  to  be  associated  with  an  increment  in  myocardial  col-
agen  cross-linking  but  not  with  changes  in  myocardial  total
ollagen  content  [34]. In  addition,  the  giant  molecule  titin
pans  half  of  the  sarcomeres  of  striated  muscle  and  accounts
or  most  of  the  passive  force  of  cardiomyocytes.  Makarenko
t  al.  [35]  reported  that  the  relationship  between  titin-
ased  and  collagen-based  passive  stiffness  is  altered  in
he  human  dilated  cardiomyopathy  heart.  We  therefore
peculate  that  both  collagen-based  and  titin-based  passive
tiffness  may  play  important  roles  in  an  increase  in  myocar-
ial  stiffness.
tudy  limitations
y  limiting  our  study  to  the  use  of  a  simple  cylindrical  model
f  LV  geometry  for  calculating  the  stress—strain  relation-
hips,  we  could  not  deal  with  hypertrophic  cardiomyopathy
r  ischemic  cardiomyopathy  because  of  the  presence  of
V  asymmetric  hypertrophy  or  asynergy.  The  number  of
atients  was  not  sufﬁcient  to  permit  a  true  multivariate
nalysis  of  the  many  predictors,  so  that  univariate  anal-
ses  were  used.  Another  limitation  is  that  the  number  of
atients  who  reached  the  primary  endpoint  was  small  com-
ared  that  reported  in  previous  studies.  Since  all  patients
ere  discharged  with  adequate  circulatory  stabilization  and
arefully  followed  up  at  our  outpatient  clinic  every  month,
e  think  that  the  re-admission  rate  of  our  study  (27%)  is
easonable.
linical  implications
he  evaluation  of  myocardial  stiffness  in  patients  with  ini-
ial  hospitalization  for  CHF  has  clinical  implications.  Our
tudy  results  suggest  that  the  primary  factor  responsible
or  recurrent  decompensation  depends  on  passive  myocar-
ial  stiffness  regardless  of  hemodynamic  and  neurohormonal
onditions.  Since  heterogeneity  in  the  symptoms  of  heart
ailure  and  in  the  prognosis  for  patients  with  impaired  dias-
olic  and/or  systolic  function  is  well  recognized,  our  method
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may  facilitate  exploration  of  the  mechanism  of  the  transi-
tion  from  any  form  of  LV  maladaptive  progressive  ﬁbrosis  to
recurrent  decompensation.
Conclusions
Although  plasma  BNP  monitoring  is  well  known  as  a  less
invasive  method  to  evaluate  CHF  prognosis,  its  prognostic
value  is  affected  by  changes  in  the  loading  conditions.  It
therefore  remains  to  be  clariﬁed  whether  plasma  BNP  moni-
toring  is  an  essential  predictor  for  CHF  patients.  On  the  other
hand,  increased  myocardial  stiffness  is  likely  to  play  a  cru-
cial  role  in  triggering  deleterious  cardiac  disorders  and  may
be  considered  to  be  an  essential  and  important  predictor  of
cardiac  death  or  re-admission  for  CHF.  Further  studies  are
needed,  however,  to  develop  an  easier  method  to  calculate
myocardial  stiffness  in  vivo.
References
[1] Cowie MR, Fox KF, Wood DA, Metcalfe C, Thompson SG, Coats
AJ, Poole-Wilson PA, Sutton GC. Hospitalization of patients
with heart failure: a population-based study. Eur Heart J
2002;23:877—85.
[2] Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and deter-
minants of survival in patients newly hospitalized for heart
failure. Arch Intern Med 2002;162:1689—94.
[3] Philbin EF, Rocco TA, Lindenmuth NW, Ulrich K, Jenkins PL.
Clinical outcomes in heart failure: report from a community
hospital-based registry. Am J Med 1999;107:549—55.
[4] Haldeman GA, Croft JB, Giles WH, Rashidee A. Hospitaliza-
tion of patients with heart failure: national hospital discharge
survey 1985—1995. Am Heart J 1999;137:352—60.
[5] Krumholz HM, Parent EM, Tu N, Vaccarino V, Wang Y, Radford
MJ, Hennen J. Readmission after hospitalization for congestive
heart failure among Medicare beneﬁciaries. Arch Intern Med
1997;157:99—104.
[6] MERIT-HF Study Group. Effect of metoprolol CR/XL in
chronic heart failure: Metoprolol CR/XL Randomized Inter-
vention trial in Congestive Heart Failure (MERIT-HF). Lancet
1999;353:2001—7.
[7] CIBIS-II Investigators and Committee. The Cardiac Insufﬁ-
ciency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet
1999;353:9—13.
[8] Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P,
Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK,
DeMets DL. Effect of carvedilol on survival in severe chronic
heart failure. N Engl J Med 2001;344:1651—8.
[9] Pozzoli M, Traversi E, Ciofﬁ G, Stenner R, Sanarico M, Tavazzi L.
Loading manipulations improve the prognostic value of Doppler
evaluation of mitral ﬂow in patients with chronic heart failure.
Circulation 1997;95:1222—30.
[10] Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beau-
vais F, Bouvier E, Solal AC. Predischarge B-type natriuretic
peptide assay for identifying patients at high risk of re-
admission after decompensated heart failure. J Am Coll Cardiol
2004;43:635—41.
[11] Dokainish H, Zoghbi WA, Lakkis NM, Ambriz E, Patel R, Quinones
MA, Nagueh SF. Incremental predictive power of B-type natri-
uretic peptide and tissue Doppler echocardiography in the
prognosis of patients with congestive heart failure. J Am Coll
Cardiol 2005;45:1223—6.
[12] Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto
I, Nishino K, Yoshimasa T, Nakao K. Rapid transcriptional acti-
vation and early mRNA turnover of brain natriuretic peptide
[251
in cardiocyte hypertrophy. Evidence for brain natriuretic pep-
tide as an ‘‘emergency’’ cardiac hormone against ventricular
overload. J Clin Invest 1995;96:1280—7.
13] Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma
brain natriuretic peptide as a biochemical marker of high
left ventricular end-diastolic pressure in patients with symp-
tomatic left ventricular dysfunction. Am Heart J 1998;135:
825—32.
14] Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki
M, Mukoyama M, Nakao K, Imura H. Different secretion
patterns of atrial natriuretic peptide and brain natriuretic
peptide in patients with congestive heart failure. Circulation
1993;87:464—9.
15] Usuku H, Nakayama M, Sumida H, Yamamuro M, Izumiya Y,
Suzuki S, Kusuhara K, Ueno H, Sugiyama S, Yoshimura M,
Ogawa H. Pump failure death and sudden cardiac death in
patients with cardiac dysfunction: A search for prognostic
predictive factors — A long-term follow-up study. J Cardiol
2010;55:55—64.
16] Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y,
Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M. Attenuation
of compensation of endogenous cardiac natriuretic peptide
system in chronic heart failure: prognostic role of plasma
brain natriuretic peptide concentration in patients with
chronic symptomatic left ventricular dysfunction. Circulation
1997;96:509—16.
17] Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P,
Gardetto N, Clopton P, Maisel A. A rapid bedside test for B-type
peptide predicts treatment outcomes in patients admitted for
decompensated heart failure: a pilot study. J Am Coll Cardiol
2001;37:386—91.
18] Watanabe S, Shite J, Takaoka H, Shinke T, Imuro Y, Ozawa T,
Otake H, Matsumoto D, Ogasawara D, Paredes OL, Yokoyama M.
Myocardial stiffness is an important determinant of the plasma
brain natriuretic peptide concentration in patients with both
diastolic and systolic heart failure. Eur Heart J 2006;27:832—8.
19] Mirsky I, Tajimi T, Peterson KL. The development of the entire
end-systolic pressure—volume and ejection fraction-after load
relations: a new concept of systolic myocardial stiffness. Cir-
culation 1987;76:343—56.
20] Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival
after the onset of congestive heart failure in Framingham Heart
Study subjects. Circulation 1993;88:107—15.
21] Saito Y. Roles of atrial natriuretic peptide and its therapeutic
use. J Cardiol 2010;56:262—70.
22] Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K,
Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K.
Localization and mechanism of secretion of B-type natriuretic
peptide in comparison with those of A-type natriuretic peptide
in normal subjects and patients with heart failure. Circulation
1994;90:195—203.
23] Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations
regarding quantitation in M-mode echocardiography: results
of a survey of echocardiographic measurements. Circulation
1978;58:1072—83.
24] Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs
I, Reichek N. Echocardiographic assessment of left ventricular
hypertrophy: comparison to necropsy ﬁndings. Am J Cardiol
1986;57:450—8.
25] Weiss JL, Frederiksen JW,  Weisfeldt ML. Hemodynamic deter-
minants of the time-course of fall in canine left ventricular
pressure. J Clin Invest 1976;58:751—60.
26] Esposito G, Santana LF, Dilly K, Cruz JD, Mao L, Lederer
WJ, Rockman HA. Cellular and functional defects in a mouse
model of heart failure. Am J Physiol Heart Circ Physiol
2000;279:H3101—12.
27] Takaoka H, Esposito G, Mao L, Suga H, Rockman HA. Heart









pressure overload hypertrophy. Am J Physiol Heart Circ Physiol
2002;282:H2190—7.
28] Grossman W, Jones D, McLaurin LP. Wall stress and patterns
of hypertrophy in the human left ventricle. J Clin Invest
1975;56:56—64.
29] Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognos-
tic value of Doppler transmitral ﬂow patterns in patients with
congestive heart failure. J Am Coll Cardiol 1994;24:132—9.
30] Gibbs M, Veliotes DG, Anamourlis C, Badenhorst D, Osadchii O,
Norton GR, Woodiwiss AJ. Chronic beta-adrenoreceptor activa-
tion increases cardiac cavity size through chamber remodeling
and not via modiﬁcations in myocardial material properties.
Am J Physiol Heart Circ Physiol 2004;287:H2762—7.
31] Yamaguchi H, Yoshida J, Yamamoto K, Sakata Y, Mano T, Akehi
N, Hori M, Lim YJ, Mishima M, Masuyama T. Elevation of plasma
brain natriuretic peptide is a hallmark of diastolic heart fail-
ure independent of ventricular hypertrophy. J Am Coll Cardiol
2004;43:55—60.S.  Watanabe  et  al.
32] Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T,
Yoshida J, Miwa T, Sugawara M, Yamaguchi Y, Ookawara T,
Suzuki K, Hori M. Myocardial stiffness is determined by ventric-
ular ﬁbrosis, but not by compensatory or excessive hypertrophy
in hypertensive heart. Cardiovasc Res 2002;55:76—82.
33] Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing
OH. Myocardial ﬁbrosis and stiffness with hypertrophy and
heart failure in the spontaneously hypertensive rat. Circulation
1995;91:161—70.
34] Norton GR, Candy G, Woodiwiss AJ. Aminoguanidine pre-
vents the decreased myocardial compliance produced by
streptozotocin-induced diabetes mellitus in rats. Circulation
1996;93:1905—12.
35] Makarenko I, Opitz CA, Leake MC, Neagoe C, Kulke M,
Gwathmey JK, del Monte F, Hajjar RJ, Linke WA. Passive
stiffness changes caused by upregulation of compliant titin
isoforms in human dilated cardiomyopathy hearts. Circ Res
2004;95:708—16.
